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Combination of HBIG and Lamivudine-
Resistant Mutations: A Formula for Trouble?
Selection of hepatitis B virus polymerase mutants
with enhanced replication by lamivudine
treatment after liver transplantation. Bock CT,
Tillmann HL, Torresi J, Klempnauer J,
Locarnini S, Manns MP, Trautwein C.
Gastroenterol 2002;122:264-273.(Reprinted
with permission from the American
Gastroenterological Association.)
Abstract
Background & Aims: Lamivudine has become a main
therapeutic option for treating hepatitis B virus (HBV)
infection. Although drug resistance develops, the clinical
course after selection of antiviral-resistant HBV mutants
seems to be benign. However, we observed a severe clinical
course of hepatitis B infection in several liver transplant
recipients after the emergence of lamivudine resistance.
This was associated with high viral load in the blood.
Methods: In this report, we characterize the molecular
mechanisms underlying drug-dependent enhanced repli-
cation of particular lamivudine-resistant HBV mutants
selected in these patients, which were associated with sud-
den onset of liver failure. Results: The clinical course was
characterized by a sudden rise in serum bilirubin, pro-
thrombin time, and transaminase. HBV sequence analysis
of these patients revealed both mutations in the “a-deter-
minant” of the envelope and the YMDD (tyrosine, methi-
onine, aspartate, aspartate) motif (domain C) of the
polymerase protein. Transfection experiments with repli-
cation competent vectors indicated that the “a-determi-
nant” changes were not associated with resistance,
whereas mutations in the YMDD motif conferred resis-
tance to lamivudine. More importantly, combinations of
mutations in the “a-determinant” and the YMDD motif
in patients with a severe hepatitis were not only resistant
to lamivudine treatment, but showed enhanced replica-
tion in vitro in the presence of lamivudine. This observa-
tion was confirmed in separate laboratories. Conclusions:
Severe and fatal hepatitis B infection can occur during
lamivudine therapy and may be associated with certain
HBV mutants selected during sequential nucleoside and
HBIg treatment. The lamivudine-enhanced replication
shown by these mutants suggests that continuation of
therapy with lamivudine could be deleterious in some
patients. (Gastroenterology 2002;122:264-273.)
Comments
The use of hepatitis B immune globulin (HBIG) and
lamivudine has resulted in excellent patient and graft
survival rates for patients who have undergone liver
transplantation for hepatitis B virus (HBV)–related
liver failure; however, HBIG is expensive. In addition,
20% to 40% of patients who received HBIG mono-
therapy develop recurrent HBV infection.1-3 Inade-
quate HBIG in patients with high viral load is the most
important cause of early HBV recurrence, whereas
selection of HBV S gene mutants is the predominant
cause of late HBV recurrence.4 Lamivudine mono-
therapy has been shown to decrease recurrent HBV
infection after liver transplantation, but the efficacy
diminishes with time because of the selection of resis-
tant mutations in the YMDD motif of the HBV poly-
merase (P) gene.5,6 The most important mutation
involves substitution of the methionine at position 204
(550 or 552 depending on the numbering system) for
valine or isoleucine (M204V/I).7 An additional muta-
tion involving substitution of leucine at position 180
(526 or 528) for methionine is present in most patients.
In vitro studies showed that the M204V/I mutants have
decreased replication fitness compared with wild-type
HBV.8 Clinical studies found that most patients with
these mutants have low HBV DNA and aminotransfer-
ase levels. Nevertheless, some patients harboring lami-
vudine resistant mutants may develop progressive liver
disease.9 Furthermore, additional mutations in the
HBV genome have been reported in some patients dur-
ing prolonged lamivudine therapy.10,11 It has been sug-
gested that these changes may represent compensatory
mutations that restore the replication fitness of HBV.
In the article by Bock et al,12 the molecular mecha-
nisms that may be responsible for the poor clinical
outcomes observed in three patients who developed
lamivudine resistance posttransplantation were pre-
sented. Of note, HBIG immunoprophylaxis and sub-
sequent therapy with famciclovir had previously failed
in all three patients. At 13, 24, and 64 weeks after the
introduction of lamivudine, progressive graft failure
developed that resulted in death or retransplantation.
Viral sequencing showed that all three patients had
M550V and L526M mutations and additional muta-
tions in the HBV P gene that corresponded to the a
determinant region of the surface (S) gene. Two
patients had a P120T mutation in the envelope region.
Using site-directed mutagenesis, they created con-
structs with individual and combined HBV P and S
gene mutations identified in these three patients. These
constructs were then transfected into human hepatoma
cells and analyzed for HBV replication fitness in the
presence or absence of lamivudine. They confirmed
that the M550V mutant was resistant to lamivudine. In
addition, they showed that constructs with combined
mutations in the P (L526MM550V) and S (P120T
or G145R) genes also were resistant to lamivudine.
Furthermore, constructs with combined P and S gene
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mutations had increased replication fitness in the pres-
ence of lamivudine compared with wild-type HBV.
The authors concluded that the enhanced replication of
the combined a-determinant and P gene mutants
observed in vitro accounted for the poor clinical course
observed in the three patients studied.
Do these study results indicate that lamivudine
should not be used in patients who developed recurrent
hepatitis B secondary to failure of HBIG prophylaxis?
Many studies have shown that lamivudine treatment of
patients who developed recurrent hepatitis B secondary
to failure of HBIG prophylaxis results in viral suppres-
sion as well as clinical improvement.13,14 Although pro-
gressive liver disease has been reported in some patients
who developed lamivudine resistance, short-term fol-
low-up (1 to 4 years) showed that most patients con-
tinue to benefit from lamivudine treatment. Bock et
al15 studied three patients with adverse outcome but
control patients who developed lamivudine resistance
during treatment for recurrent hepatitis B after liver
transplantation and who had stable clinical course were
not examined. Thus, the causal relationship between
their findings and clinical outcome remain to be estab-
lished. Previous studies found that in most patients,
mutations in the a-determinant revert back to wild-type
S sequence after discontinuation of HBIG. It is surpris-
ing that the a-determinant mutants persisted in these
three patients. Unfortunately, the pretransplant viral
sequences were not reported and the exact timing of
sequence analysis in relation to discontinuation of
HBIG was not provided. The rapidity with which
breakthrough infection occurred after initiation of
lamivudine therapy was also unusual and may be related
to prior treatment failure with famciclovir. L526M
mutation has been reported in patients with famciclovir
resistance.16 Although the investigators were unable to
detect this mutation at the onset of lamivudine therapy,
it is possible that preselection of the L526M mutation
has occurred, albeit at low levels. This may account for
the rapid selection of the M550V mutation on intro-
duction of lamivudine. Results of this study argue
against sequential therapy of weak antiviral agents.
Despite the shortcomings of this study, Bock et al12
showed that additional or compensatory mutations
restore and even enhance replication fitness of lamivu-
dine-resistant HBV mutants. Similar findings have
been reported in the HIV literature.17 Thus, patients
who are maintained on lamivudine therapy after the
emergence of lamivudine resistance must be closely
monitored. Further studies are needed to confirm the
findings of Bock et al and to identify the factors that are
associated with adverse clinical outcome in patients
with lamivudine resistance. As new antiviral agents with
efficacy against lamivudine resistant HBV such as
adefovir, tenofovir, and entecavir become available, the
management of patients with lamivudine resistance will
need to be reassessed.18,19 Addition or substitution of
these new agents for lamivudine will likely be recom-
mended. This is particularly important for patients who
have developed lamivudine resistance prior to liver
transplantation.
This study raised other intriguing questions. Will
patients with vaccine escape a-determinants in the HBV S
gene have decreased response to lamivudine therapy or
worse outcome when they develop lamivudine resistance?
Two decades after the introduction of HBV vaccination,
there is no proof that the efficacy of current HBV vaccines
is declining and no evidence that the prevalence of a-de-
terminant mutants in the community is increasing. Thus,
the question raised may be irrelevant. Of more concern to
the transplant community is the efficacy of combination
prophylaxis with lamivudine and HBIG in the prevention
of HBV recurrence in patients who had been on lamivu-
dine monotherapy for extended duration before trans-
plantation. To date, most studies using combination pro-
phylaxis have reported recurrence rates of less than
10%.20-22 However, several investigators found that
despite the use of combination prophylaxis, HBV recur-
rence occurred in most patients who had lamivudine resis-
tance before transplantation.23,24 Whether the treatment
failures were attributable to suboptimal dose of HBIG,
enhanced HBV replication secondary to combination of
HBV P and S gene mutations, or diminished efficacy of
HBIG in patients with lamivudine resistant mutations
remain to be determined. It has been suggested that lami-
vudine-resistant P gene mutations may lead to changes in
the overlapping S gene, thereby decreasing the affinity of
the HBV surface protein for HBIG. This concern has not
been proven, but merit studying as combination prophy-
laxis with HBIG and lamivudine is the standard in most
transplant centers.
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